NodThera is developing a new class of potent and highly selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. We're building a dynamic team of people across our offices in Cambridge, UK; Seattle, WA; and Lexington, MA; all united by our shared ambition, enthusiasm, and creativity.